Search Result

Results for "

antitumoral

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Aminopeptidase (1) Apoptosis (10) Autophagy (2) Bacterial (3) Caspase (1) CDK (1) Cytochrome P450 (6) DGK (2) DNA/RNA Synthesis (1) Epigenetic Reader Domain (2) Fungal (1) G-quadruplex (1) HDAC (3) Insulin Receptor (2) Isotope-Labeled Compounds (2) MetAP (1) Microtubule/Tubulin (1) Neurokinin Receptor (1) Parasite (2) PD-1/PD-L1 (1) Peptide-Drug Conjugates (PDCs) (2) PKC (2) PROTACs (1) Proteasome (2) RAR/RXR (5) Reference Standards (5) Topoisomerase (1) YAP (1)
By Research Areas:	Cancer (42) Cardiovascular Disease (4) Endocrinology (2) Infection (5) Inflammation/Immunology (11) Metabolic Disease (7) Neurological Disease (1)

By Targets:

Aminopeptidase (1)

Apoptosis (10)

Autophagy (2)

Bacterial (3)

Caspase (1)

CDK (1)

Cytochrome P450 (6)

DGK (2)

DNA/RNA Synthesis (1)

Epigenetic Reader Domain (2)

Fungal (1)

G-quadruplex (1)

HDAC (3)

Insulin Receptor (2)

Isotope-Labeled Compounds (2)

MetAP (1)

Microtubule/Tubulin (1)

Neurokinin Receptor (1)

Parasite (2)

PD-1/PD-L1 (1)

Peptide-Drug Conjugates (PDCs) (2)

PKC (2)

PROTACs (1)

Proteasome (2)

RAR/RXR (5)

Reference Standards (5)

Topoisomerase (1)

YAP (1)

By Research Areas:

Cancer (42)

Cardiovascular Disease (4)

Endocrinology (2)

Infection (5)

Inflammation/Immunology (11)

Metabolic Disease (7)

Neurological Disease (1)

Inhibitors & Agonists

Peptides

Natural
Products

Isotope-Labeled Compounds

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-128763

HDAC-IN-4	HDAC	Cancer
HDAC-IN-4 is a selective HDAC6 and HDAC10 inhibitor with pIC₅₀s of 7.2 and 6.8 in BRET assay, respectively. Antitumoral activity .

HY-N7190

Yadanzioside F	Parasite	Cancer
Yadanzioside F is one of the toxic components found in Brucea javanica . Brucea javanica has demonstrated a variety of antitumoral, antimalarial, and anti-inflammatory properties .

HY-13626

Spisulosine 1 Publications Verification ES-285	PKC Apoptosis	Cancer
Spisulosine (ES-285) is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKCζ activation. Spisulosine induces apoptosis in PC-3 and LNCaP cells .

HY-14406A

L-733060 hydrochloride 1 Publications Verification	Neurokinin Receptor	Neurological Disease Cancer
L-733060 hydrochloride is a potent tachykinin NK₁ receptor antagonist. L-733060 hydrochloride inhibits neurogenic plasma extravasation at doses that do not cause adverse cardiovascular effects in rodents and also acts as an antitumoral agent .

HY-101144

RSM-932A TCD-717	Others	Cancer
RSM-932A (TCD-717) is a specific ChoKα inhibitor with IC₅₀s of 1 and 33 μM for human recombinant ChoKα and ChoKβ enzymes, respectively. RSM-932A acts as the “first in humans” compound targeting ChoKα. RSM-932A is potent in vitro anti-proliferative and in vivo anti-tumoral activity against human xenografts in mice, showing high efficacy with low toxicity profiles .

HY-133016

M8891	MetAP	Cardiovascular Disease Cancer
M8891 is an orally active, reversible and brain penetrant Methionine Aminopeptidase-2 (MetAP-2) inhibitor with an IC₅₀ of 54 nM and a K_i of 4.33 nM. M8891 does not inhibit MetAP-1 (IC₅₀>10 µM) . M8891 inhibits growth of primary endothelial cells as well as tumor cells and demonstrates antiangiogenic and antitumoral activity .

HY-120102

Emicoron	G-quadruplex	Cancer
Emicoron is a new promising G4 ligand and bind G-rich oncogene promoters. Emicoron possesses a marked antitumoral activity? alone or in combination with chemotherapeutics in vivo. Emicoron can be used for cancer research .

HY-148592

Antitumor agent-87	Cytochrome P450	Cancer
Antitumor agent-87 is a potent antitumor agent. Antitumor agent-87 shows a high affinity for CYP1A1 with a K_i value of 0.23 µM. Antitumor agent-87 shows antiproliferative activity. Antitumor agent-87 induces cell cycle arrest at the G2/M phase. Antitumor agent-87 show antitumoral activity .

HY-164487

JBJ-08-178-01	Proteasome	Cancer
JBJ-08-178-01 is a mutant-selective tyrosine kinase inhibitor against human epidermal growth factor receptor 2 (HER2) with an antitumoral activity. JBJ-08-178-01 reduces both the kinase activity and protein levels of HER2 by inducing proteasomal degradation of the receptor in lung cancer. JBJ-08-178-01 is promising for research of non-small-cell lung cancer .

HY-P10759

DTS-201 sodium	Peptide-Drug Conjugates (PDCs) Aminopeptidase	Cancer
DTS-201 sodium (CPI-0004Na) is a peptidic prodrug of Doxorubicin (HY-15142A). DTS-201, comprising the tetrapeptide portion, is cleaved by endopeptidases in the tumor environment to produce metabolites that subsequently enter the cell and are converted to active Doxorubicin. DTS-201 shows antitumoral efficacy in tumor xenograft models of prostate, breast, and lung cancer .

HY-105273

Erbulozole R 55104	Microtubule/Tubulin	Cancer
Erbulozole (R 55104) is a microtubule inhibitor with antitumoral effects .

HY-N0187

4-Methylumbelliferone 5+ Cited Publications Hymecromone; 4-MU	Others	Cardiovascular Disease Cancer
4-Methylumbelliferone is a hyaluronic acid biosynthesis inhibitor with antitumoral and antimetastatic effects.

HY-N0628

Kaempferitrin 2 Publications Verification Lespedin; Lespenephryl	Insulin Receptor	Metabolic Disease Endocrinology Cancer
Kaempferitrin is a natural flavonoid, possesses antinociceptive, anti-inflammatory, anti-diabetic, antitumoral and chemopreventive effects, and activates insulin signaling pathway.

HY-N0187R

4-Methylumbelliferone (Standard) Hymecromone (Standard); 4-MU (Standard)	Reference Standards Others	Cardiovascular Disease Cancer
4-Methylumbelliferone (Standard) is the analytical standard of 4-Methylumbelliferone. This product is intended for research and analytical applications. 4-Methylumbelliferone is a hyaluronic acid biosynthesis inhibitor with antitumoral and antimetastatic effects.

HY-120350

BI-1347 2 Publications Verification	CDK	Cancer
BI-1347 is an orally active, selective and potent CDK8 inhibitor (IC₅₀=1.1 nM). BI-1347 shows anti-tumoral activity .

HY-N0628R

Kaempferitrin (Standard) Lespedin (Standard); Lespenephryl (Standard)	Reference Standards Insulin Receptor	Metabolic Disease Endocrinology Cancer
Kaempferitrin (Standard) is the analytical standard of Kaempferitrin. This product is intended for research and analytical applications. Kaempferitrin is a natural flavonoid, possesses antinociceptive, anti-inflammatory, anti-diabetic, antitumoral and chemopreventive effects, and activates insulin signaling pathway.

HY-N13904

Argyrin A	Proteasome	Cancer
Argyrin A, a cyclical peptide, is a potent antitumoral agent. Argyrin A exerts its effects through a potent inhibition of the proteasome. Argyrin A leads to increased endogenous p27 ^kip1 levels by preventing protein turnover .

HY-108431

MN58b 1 Publications Verification	Apoptosis	Cancer
MN58b is a selective choline kinase α (CHKα) inhibitor, and results in inhibition of phosphocholine synthesis. MN58b reduces cell growth through the induction of apoptosis, and also has antitumoral activity .

HY-N0187S

4-Methylumbelliferone-13C4 Hymecromone-¹³C₄; 4-MU-¹³C₄	Isotope-Labeled Compounds	Cancer
4-Methylumbelliferone- ¹³C₄ (Hymecromone- ¹³C₄) is the ¹³C-labeled 4-Methylumbelliferone (HY-N0187). 4-Methylumbelliferone is a hyaluronic acid biosynthesis inhibitor with antitumoral and antimetastatic effects.

HY-N10402

Norbatzelladine L	Fungal Bacterial Parasite	Infection Cancer
Norbatzelladine L (Compound 2) is an inhibitor of the catalytic and functional activity of Pdr5p transporter. Norbatzelladine L inhibits Pdr5p ATPase activity with an IC₅₀ of 3.8 µM. Norbatzelladine L shows antifungal, antiparasitic, antiviral, antibacterial and antitumoral activities .

HY-N0757

8-O-Acetylharpagide	Bacterial	Infection Inflammation/Immunology Cancer
8-O-Acetylharpagide is an iridoid isolated from Ajuga reptans with antitumoral, antiviral, antibacterial, and anti-inflammatory activities. 8-O-Acetylharpagide also has a biological activity on isolated smooth muscle preparations from guinea pig .

HY-136342

Antitumor agent-23	Others	Cancer
Antitumor agent-23 is a potent anti-cancer agent with GI₅₀s of 38, 48, 5, 27, 80, and 28 nM for lymphoma cell line GRANTA-519, KARPAS-422, KARPAS-299, RAMOS, DAUDI, and RAJI, respectively. Antitumoral activity .

HY-U00337A

Datelliptium chloride hydrochloride	DNA/RNA Synthesis	Cancer
Datelliptium chloride hydrochloride is a DNA-intercalating agent derived from Ellipticine (HY-15753). Datelliptium chloride hydrochloride is effective in vivo against a variety of murine solid tumors .

HY-15433A

Quisinostat dihydrochloride Maximum Cited Publications 15 Publications Verification JNJ-26481585 dihydrochloride	HDAC Apoptosis Autophagy	Cancer
Quisinostat dihydrochloride (JNJ-26481585 dihydrochloride) is an orally available, potent pan-HDAC inhibitor with IC₅₀s of 0.11 nM, 0.33 nM, 0.64 nM, 0.46 nM, and 0.37 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11, respectively. Quisinostat dihydrochloride has a broad spectrum antitumoral activity .

HY-P2970

Stem bromelain	Apoptosis	Inflammation/Immunology Cancer
Stem bromelain (EC 3.4.22.32) is a cysteine proteinase, can be isolated from pineapple (Ananas comosus) stem. Stem bromelain is a major bromelain, which exhibits various fibrinolytic, antiedematous, antithrombotic, and anti-inflammatory activities. Stem bromelain has in vivo antitumoral and antileukemic activity, as well as antimetastatic action .

HY-106019A

Liarozole hydrochloride R75251 hydrochloride	Cytochrome P450 RAR/RXR	Metabolic Disease Inflammation/Immunology Cancer
Liarozole hydrochloride is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole hydrochloride inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of retinoic acid (IC₅₀=7 μM), resulting in increased tissue levels of retinoic acid. Liarozole hydrochloride shows antitumoral properties .

HY-106019C

Liarozole dihydrochloride R75251 dihydrochloride	Cytochrome P450 RAR/RXR	Metabolic Disease Inflammation/Immunology Cancer
Liarozole (R75251) dihydrochloride is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole dihydrochloride inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of RA (IC₅₀=7 μM), resulting in increased tissue levels of RA. Liarozole dihydrochloride shows antitumoral properties .

HY-15433

Quisinostat Maximum Cited Publications 15 Publications Verification JNJ-26481585	HDAC Apoptosis Autophagy	Cancer
Quisinostat (JNJ-26481585) is a potent, second-generation and orally active pan-HDAC inhibitor (HDACi), with IC₅₀ values ranging from 0.11 nM to 0.64 nM for HDAC1, HDAC2, HDAC4, HDAC10 and HDAC11. Quisinostat has a broad spectrum antitumoral activity . Quisinostat can induce autophagy in neuroblastoma cells .

HY-106019

Liarozole R75251	Cytochrome P450 RAR/RXR	Metabolic Disease Inflammation/Immunology Cancer
Liarozole (R75251; R85246) is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of retinoic acid (IC₅₀=7 μM), resulting in increased tissue levels of retinoic acid. Liarozole shows antitumoral properties .

HY-13626S

Spisulosine-d3 ES-285-d₃	Isotope-Labeled Compounds PKC Apoptosis	Cancer
Spisulosine-d₃ (ES-285-d₃) is deuterium labeled Spisulosine (HY-13626). Spisulosine is an antiproliferative (antitumoral) compound of marine origin. Spisulosine inhibits the growth of the prostate PC-3 and LNCaP cells through intracellular ceramide accumulation and PKCζ activation. Spisulosine induces apoptosis in PC-3 and LNCaP cells .

HY-N0757R

8-?O-?Acetylharpagide (Standard)	Reference Standards Bacterial	Infection Inflammation/Immunology Cancer
8-O-Acetylharpagide (Standard) is the analytical standard of 8-O-Acetylharpagide. This product is intended for research and analytical applications. 8-O-Acetylharpagide is an iridoid isolated from Ajuga reptans with antitumoral, antiviral, antibacterial, and anti-inflammatory activities. 8-O-Acetylharpagide also has a biological activity on isolated smooth muscle preparations from guinea pig .

HY-N13944

Argyrin F	Apoptosis	Cancer
Argyrin F a cyclic peptide with antitumoral activities. Argyrin F inhibits cell proliferation, migration, invasion and colony formation by partial induction of apoptosis and epithelial-mesenchymal transition (EMT). Argyrin F stabilizes p27 ^kip, up-regulated p21 ^waf1/cip1 and depletes COX2. Argyrin F can be used for the study of pancreatic ductal adenocarcinoma (PDAC) .

HY-106019CR

Liarozole dihydrochloride (Standard) R75251 dihydrochloride (Standard)	Reference Standards Cytochrome P450 RAR/RXR	Metabolic Disease Inflammation/Immunology Cancer
Liarozole (dihydrochloride) (Standard) is the analytical standard of Liarozole (dihydrochloride). This product is intended for research and analytical applications. Liarozole (R75251) dihydrochloride is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole dihydrochloride inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of RA (IC50=7 μM), resulting in increased tissue levels of RA. Liarozole dihydrochloride shows antitumoral properties .

HY-106019R

Liarozole (Standard) R75251 (Standard)	Reference Standards Cytochrome P450 RAR/RXR	Metabolic Disease Inflammation/Immunology Cancer
Liarozole (Standard) is the analytical standard of Liarozole. This product is intended for research and analytical applications. Liarozole (R75251; R85246) is an imidazole derivative and orally active retinoic acid (RA) metabolism-blocking agent (RAMBA). Liarozole inhibits the cytochrome P450 (CYP26)-dependent 4-hydroxylation of retinoic acid (IC50=7 μM), resulting in increased tissue levels of retinoic acid. Liarozole shows antitumoral properties .

HY-P10765

DTS-108	Peptide-Drug Conjugates (PDCs) Topoisomerase	Cancer
DTS-108 is a prodrug of SN38 (HY-13704) (a Topoisomerase I inhibitor). DTS-108 is a conjugate generated by linking SN38 to a human oligopeptide via an esterase sensitive cross-linker. DTS-108 exhibits anti-tumor activity against colorectal, lung, and mammary cancer .

HY-P10947

MACTIDE-V	Epigenetic Reader Domain YAP	Cancer
MACTIDE-V is an orally active and selective peptide-drug conjugate targeting CD206. MACTIDE-V delivers Verteporfin (HY-B0146) to CD206 ⁺ tumor-associated macrophages (TAM) to inhibit the YAP/TAZ signaling pathway, prompting YAP exclusion from the nucleus, inducing TAM polarization toward an anti-tumoral phenotype with enhanced phagocytosis and antigen presentation, and boosting T cell infiltration and NK cell activity. MACTIDE-V suppresses primary tumor growth and lung metastasis in triple-negative breast cancer (TNBC) mouse models .

HY-174811

PROTAC BRD4 Degrader-33	PROTACs Epigenetic Reader Domain PD-1/PD-L1	Inflammation/Immunology Cancer
PROTAC BRD4 Degrader-33 is an enzyme activated clickable BRD4 PROTAC degrader with favorable tumor microenvironment-response. PROTAC BRD4 Degrader-33 has superior tumor tissue penetration capabilities and efficiently inhibits PD-L1 protein expression. PROTAC BRD4 Degrader-33 shows potent anti-tumoral immunomodulation activity in 4T1 tumor-bearing mice model . Pink: BRD4 ligand (HY-174812); Blue: CRBN ligase ligand (HY-10984); Black: linker

HY-121638A

(5Z,2E)-CU-3 1 Publications Verification	Apoptosis DGK	Cancer
(5Z,2E)-CU-3 is a potent and selective inhibitor against the α-isozyme of DGK with an IC₅₀ value of 0.6 μM, competitively inhibits the affinity of DGKα for ATP with a K_m value of 0.48 mM. (5Z,2E)-CU-3 targets the catalytic region, but not the regulatory region of DGKα. (5Z,2E)-CU-3 has antitumoral and proimmunogenic effects, enhances the apoptosis of cancer cells and the activation of T cells .

HY-130326

RAPTA-C Ru(η6-p-cymene)Cl2(pta)	Apoptosis Caspase	Cardiovascular Disease Cancer
RAPTA-C (Ru(η6-p-cymene)Cl2(pta)) acts as an anti-cancer and anti-angiogenic agent. RAPTA-C exhibits anti-metastatic, anti-angiogenic, and anti-tumoral activities through protein and histone-deoxyribonucleic acid alterations. RAPTA-C exhibits cell growth inhibition by triggering G(2)/M phase arrest in cancer cells. RAPTA-C also enhances the levels of p53 and triggers the mitochondrial Apoptotic pathway, resulting in cytochrome C release and caspase-9 activation. RAPTA-C reduces the growth of tumors with the inhibition of angiogenesis in a ovarian carcinoma model .

HY-121638

CU-3	Apoptosis DGK	Inflammation/Immunology Cancer
CU-3 is the racemate of (5Z,2E)-CU-3. (5Z,2E)-CU-3 is a potent and selective inhibitor against the α-isozyme of DGK with an IC₅₀ value of 0.6 μM, competitively inhibits the affinity of DGKα for ATP with a K_m value of 0.48 mM. (5Z,2E)-CU-3 targets the catalytic region, but not the regulatory region of DGKα. (5Z,2E)-CU-3 has antitumoral and proimmunogenic effects, enhances the apoptosis of cancer cells and the activation of T cells .

Cat. No.	Product Name	Target	Research Area

HY-P5581

Alloferon 1	Peptides	Infection Inflammation/Immunology Cancer
Alloferon 1 is an antiviral and antitumoral peptide. Alloferon 1 stimulates natural cytotoxicity of human peripheral blood lymphocytes. Alloferon 1 also induces IFN synthesis, and enhances antiviral and antitumor resistance in mice. Alloferon 1 also shows anti-inflammatory activity in λ-carrageenan-induced paw edema model. Alloferon 1 can be isolated from the blood of the blow fly Calliphora vicina (Diptera) .

HY-P5579

Alloferon 2	Peptides	Infection Cancer
Alloferon 2 is an antiviral and antitumoral peptide. Alloferon 2 can be isolated from the blood of the blow fly Calliphora vicina (Diptera) .